A prospective observational study of the effect of ANamorelin Administration on combined immunochemotherapy in patients with non-small cell lung cancer (SPIRAL-ANA study)

Clinical Research Support Center Kyushu(CReS Kyushu)0 个研究点目标入组 127 人开始时间: 2021年9月8日最近更新: 2025年4月24日

适应症

试验速览

暂无简介。

•Patients aged 20 or older at the time of informed consent).
•Patients who are to receive combined immunochemotherapy and who are to receive anamorelin 7 days prior to and on the same day as the first dose.
•Patients with histologically or cytologically confirmed non-small cell lung cancer.
•Patients with Stage III/IV or postoperative recurrence who are not eligible for radical radiation therapy or resection.
•Patients with positive driver gene should be treated with kinase inhibitors.
•Patients who have not been treated with cell-killing anticancer agents for advanced stage or postoperative recurrence lung cancer. However, preoperative and postoperative adjuvant chemotherapy is acceptable.
•Patients who meet the criteria for administration of anamorelin.
•Patients with weight loss of 5% or more and anorexia within 6 months, and at least 2 of the following (1) to (3)
•(1) Fatigue or malaise
•(2) General muscle weakness
•(3) CRP level >0.5 mg/dl, albumin level <3.2 g/dL, hemoglobin level <12 g/dl
•Patients with at least one measurable lesion in accordance with RECISTv1.1 criteria.
•Patients with a Performance Status (ECOG) of 0-
•Patients who are expected to survive for at least 3 months.
•Patients for whom written consent has been obtained from the patient.

•Patients with contraindications to anamorelin administration.
•(1) Patients with congestive heart failure
•(2) Patients with myocardial infarction or angina pectoris
•(3) Patients with severe stimulation conduction system disorder (e.g. complete atrioventricular block)
•(4) Patients receiving the following drugs: clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, telaprevir, voriconazole, ritonavir-containing products, cobicistat-containing products.
•(5) Patients with moderate or severe hepatic dysfunction (Child-Pugh classification B and C)
•(6) Patients with a history of hypersensitivity to any component of anamorelin.
•(7) Patients with difficulty in oral intake of food due to organic abnormalities of the gastrointestinal tract such as gastrointestinal obstruction.
•Patients with poorly controlled diabetes mellitus.
•Patients with intractable nausea and vomiting, chronic gastrointestinal disorders, inability to swallow preparations, or a history of gastrectomy or other procedures that may significantly affect the absorption of anamorelin.
•Other patients who are deemed inappropriate for this study by the physician in charge or others.

Progression free survival (PFS)

发起方

Clinical Research Support Center Kyushu(CReS Kyushu)